Bladder cancer, if caught early, has an impressive survival rate of over 80%. However, this number drops drastically if the disease is detected late.
Now, a groundbreaking study in The Journal of Molecular Diagnostics offers hope for early diagnosis, potentially reducing costly and uncomfortable tests.
The Significance of Blood in Urine
Blood in the urine, or hematuria, is often the first warning sign of bladder cancer, being present in around 85% of those with the disease. It’s responsible for up to 20% of visits to urology clinics.
Yet, blood in urine can be common for many adults and isn’t always a sign of cancer. In fact, only 5-20% of hematuria cases end up being diagnosed as bladder cancer.
This poses a challenge: how to effectively identify who among these patients truly has cancer?
The Challenge of Current Testing Methods
Currently, the medical world relies heavily on a test called cystoscopy to diagnose bladder cancer in people with hematuria. However, this test can be invasive, expensive, and might not always catch cancer in its early stages.
Dr. Sungwhan An, a lead investigator of the study, stressed the importance of early diagnosis. He said, “Catching bladder cancer early doesn’t just improve survival rates.
It can also help bring down the healthcare costs.” Dr. Ju Hyun Shin added, “There’s a clear need for a method that’s precise and sensitive to spot early bladder cancer among patients with hematuria.”
The Potential of the mePENK Test
The researchers decided to focus on a new marker called aberrant PENK methylation (mePENK). Past studies have shown that this marker is often present in bladder cancer patients.
The team developed a test using this marker and tried it on urine samples from people with hematuria. The results were promising.
In an initial study, the test could distinguish between cancerous and non-cancerous cases with about 87% accuracy.
In a larger follow-up study, the test was able to spot bladder cancer in 84.2% of cases, with a whopping 95.7% specificity. This means that the test rarely mistook other conditions for cancer.
Even more impressive? The test was particularly effective at detecting severe cases of bladder cancer, catching them 92.3% of the time.
Compared to other tests on the market, the mePENK test stands out.
Dr. An pointed out that while many tests use multiple markers to detect bladder cancer, their test relies on just one. Yet, it performs just as well, if not better, than the others.
Another big plus? The test uses a simple urine sample, making it less invasive and quicker to process.
Dr. An said, “Our study presents a huge leap forward in bladder cancer diagnosis. We can potentially skip the uncomfortable cystoscopy procedures.”
Dr. Shin added, “While some tests have been approved by agencies like the FDA, they haven’t been widely adopted for early diagnosis. Our test offers a compelling alternative.”
Looking Ahead
Bladder cancer is the sixth most diagnosed cancer globally. While its early-stage survival rate is high, late-stage detection can be deadly. It’s also one of the most expensive cancers to treat.
This new test offers a glimmer of hope. Not only could it increase early detection rates, but it could also bring down the high medical costs associated with bladder cancer.
However, before the test becomes a regular part of clinical practice, larger studies are needed. As Dr. An concluded, “We’re actively working towards that.”
If you care about cancer, please read studies about a new method to treat cancer effectively, and this low-dose, four-drug combo may block cancer spread.
For more information about cancer prevention, please see recent studies about nutrient in fish that can be a poison for cancer, and results showing this daily vitamin is critical to cancer prevention.
The study was published in The Journal of Molecular Diagnostics.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
